Equity Overview
Price & Market Data
Price: $4.65
Daily Change: -$0.09 / 1.94%
Daily Range: $4.53 - $4.79
Market Cap: $363,289,632
Daily Volume: 458,328
Performance Metrics
1 Week: 7.39%
1 Month: 32.10%
3 Months: 52.46%
6 Months: 32.86%
1 Year: 48.09%
YTD: 30.25%
Company Details
Employees: 56
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.